News

Most recently, Mr Lonergan served as vice president of sales, marketing, and business development for Ibis Biosciences. Prior to Ibis, Mr Lonergan held similar executive positions at 454

According to the company, the interim results indicate that sequential treatment of plaque psoriasis with Clobex spray followed by Vectical ointment is effective in managing plaque psoriasis over

In the initial stage of the program, Proteros will leverage its expertise in gene-to-structure projects and its proprietary technologies to solve the three dimensional structure of an undisclosed

CV Therapeutics, a biopharmaceutical company, has announced that CVT-3619, a novel oral compound for potential treatment of cardiometabolic diseases, was well tolerated with no serious adverse events and

The company reported revenues of $147.2 million for the first quarter ended January 31, 2009, a decrease of 10.4%, compared to $164.2 million for the corresponding period of

In his new role, Mr Kandera will be responsible for the global finance function and investor relations of Intercell. Mr Kandera is currently CFO of Intercell’s US subsidiary

Savella (milnacipran HCl), was approved by the FDA on January 14, 2009 and was originally expected to be available in March 2009. The companies submitted a minor post-approval

“In 2008, we put an experienced staff in place to establish the company as a market leader in personalized healthcare and focus our business strategy on increasing revenue

Mr Fan will report to Jinan Song, the company’s chairman and CEO, and will be responsible for all aspects of China-Biotics’s finance functions, including accounting, financial planning, tax,